Market Cap 345.04M
Revenue (ttm) 79.91M
Net Income (ttm) -27.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -33.96%
Debt to Equity Ratio 3.02
Volume 124,000
Avg Vol 189,146
Day's Range N/A - N/A
Shares Out 33.08M
Stochastic %K 84%
Beta 1.91
Analysts Strong Sell
Price Target $16.75

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data m...

Industry: Medical Devices
Sector: Healthcare
Phone: 650 237 2700
Fax: 650 237 2701
Address:
455 North Bernardo Avenue, Mountain View, United States
highnihilism
highnihilism Oct. 1 at 7:30 AM
$NPCE Neuropace Trade Count: 3 | Total $: 7.3 K | 1.43 × 90-Day Avg $: 5.1 K | Call $: 7.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $TUR iShares MSCI Turkey ETF Trade Count: 42 | Total $: 9.7 K | 0.32 × 90-Day Avg $: 30.1 K | Call $: 7.3 K | Put $: 2.4 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CNO Cno Finl Group Trade Count: 1 | Total $: 7.3 K | 2.79 × 90-Day Avg $: 2.6 K | Call $: 7.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $OCFT Oneconnect Financial Technology Trade Count: 5 | Total $: 7.3 K | 0.61 × 90-Day Avg $: 11.9 K | Call $: 7.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
Jonjon1234
Jonjon1234 Sep. 17 at 8:10 PM
$NPCE Drug resistant Epilepsy check! Focal and generalized Epilepsy in the not so distant future. Be patient with $NPCE as it’s the early innings.
1 · Reply
highnihilism
highnihilism Sep. 17 at 11:32 AM
IWM: Russell 2000 → $CBNK Capital Bancorp $NPCE Neuropace $HBT HBT Financial $DSGR Distribution Solutions $QCRH QCR
0 · Reply
HodlCommander
HodlCommander Sep. 12 at 5:46 PM
AlphaBriefing’s deep dive into quantum sensors in living cells and BCIs also features $NPCE (Neuropace). An interesting angle for neurotech investors. Read the article: https://www.alphabriefing.com/quantum-sensors-inside-living-cells-the-next-frontier-for-brain-computer-interfaces/
0 · Reply
johnemac
johnemac Aug. 25 at 3:54 PM
$NPCE Purely antidote but my son has not had a seizure since his Feb surgery with RNS and his wife comments on his improved memory, both goals for the surgery. Given good earnings, margins, forecasts and upcoming study results this should be higher but multiple factors.
0 · Reply
jacksonjohn750
jacksonjohn750 Aug. 19 at 1:26 PM
$NPCE will FDA knock them?
1 · Reply
CH_Expat
CH_Expat Aug. 15 at 4:58 PM
$NPCE @RocketThief You already pulled the trigger?
1 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:00 PM
Wells Fargo has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Overweight with a target price of 17 → 15.
0 · Reply
DonCorleone77
DonCorleone77 Aug. 12 at 8:28 PM
$NPCE NeuroPace reports Q2 EPS (26c), consensus (22c) -- Q2 revenue $23.52M, consensus $23.08M. -- Raises FY25 revenue view to $94M-$98M from $93M-$97M, consensus $94.78M. -- On track to submit Nautilus data to FDA in 2H
0 · Reply
ChessGM
ChessGM Aug. 6 at 4:46 PM
"Heads up alert! Upcoming earnings on Tuesday, 8/12/2025 for $NPCE Bullish (7.8) ### Financial Analysis NeuroPace, Inc. (NASDAQ: NPCE) is demonstrating considerable momentum in the medical technology sector, particularly in the niche of epilepsy management with its neurostimulator devices. The company's strategic response to the Centers for Medicare & Medicaid Services (CMS) decision to maintain the current reimbursement structure is crucial, as it ensures consistent revenue streams from its primary product offerings. As NeuroPace approaches its financial results announcement for the second quarter of 2025, expectations are centered around continued revenue growth and operational efficiency improvements under the new CFO, Patrick F. Williams. The company's P/E ratio, while not directly stated, is expected to reflect its rapid growth phase, potentially higher than industry averages due to the strategic market position and innovation-driven portfolio. NeuroPace's EPS growth is anticipated to be robust, aligning with the broader trend of increasing adoption of neurostimulator technology. Revenue forecasts are optimistic, bolstered by the maintained CMS reimbursement strategy, which is expected to drive both top-line growth and market confidence. Compared to industry peers such as AngioDynamics (ANGO), NeuroPace's focus on niche markets and specialized technology provides a competitive edge, although it also subjects the company to specific regulatory and market risks. ### Upcoming Earnings Report NeuroPace is scheduled to release its second-quarter 2025 financial results on August 12. Historically, the company has shown a pattern of steady financial improvement, and analyst consensus estimates suggest a continuation of this trend. The upcoming report is expected to highlight revenue growth and potential EPS improvements, driven by strategic decisions and operational refinements. Analyst consensus is cautiously optimistic, predicting that the company's recent management changes and strategic focus will positively impact the stock. The potential impact on the stock will largely depend on whether the company meets or exceeds these expectations, with a significant beat likely to further enhance investor sentiment. ### Sector Performance NeuroPace operates within the broader medical technology sector, which has been experiencing robust growth driven by innovation and increased healthcare spending. The sector's performance is marked by a strong demand for cutting-edge medical devices and technologies, particularly those addressing chronic conditions like epilepsy. Companies within this sector are benefiting from favorable regulatory environments and advancements in healthcare technology. NeuroPace, with its specialized focus, is well-positioned to capitalize on these trends, though it remains crucial for the company to navigate the regulatory landscape effectively to maintain its growth trajectory. - Funds were net buyers of $NPCE during the previous reporting quarter. - Funds with large holdings in $NPCE include: - OrbiMed Advisors LLC, MV: $42MM. Fund Rank: 55% www.orbimed.com - Soleus Capital , MV: $32MM. Fund Rank: 54% - First Light Asset Management LLC, MV: $19MM. New position. Fund Rank: 55% www.firstlightam.com - Armistice Capital LLC, MV: $14MM. Fund Rank: 72% www.armisticecapital.com - Deerfield Management Co, MV: $6MM. New position. Fund Rank: 90% www.deerfield.com - Last 10 days performance: -3% - Last 30 days performance: -16% - Last 90 days performance: -28% Some of the latest news articles: - Title: Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates Publication Date: 8/5/2025 12:25:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/orthofix-ofix-q2-earnings-revenues-122503319.html?.tsrc=rss - Title: NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases Publication Date: 8/1/2025 11:30:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/neuropace-commends-cms-maintaining-fy25-113000625.html?.tsrc=rss - Title: NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 Publication Date: 7/29/2025 8:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/neuropace-report-second-quarter-2025-200500610.html?.tsrc=rss - Title: AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates Publication Date: 7/15/2025 11:40:02 AM, Source: yahoo URL: https://finance.yahoo.com/news/angiodynamics-ango-reports-q4-loss-114002208.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."
0 · Reply
Latest News on NPCE
NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 28, 2025, 8:00 AM EDT - 5 weeks ago

NeuroPace to Participate in Upcoming Healthcare Conferences


NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:50 PM EDT - 7 weeks ago

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript


NeuroPace Announces Strategic CFO Transition

Jun 24, 2025, 4:05 PM EDT - 3 months ago

NeuroPace Announces Strategic CFO Transition


NeuroPace Secures Up to $75 Million in Debt Financing

Jun 4, 2025, 4:09 PM EDT - 4 months ago

NeuroPace Secures Up to $75 Million in Debt Financing


NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:33 PM EDT - 5 months ago

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript


NeuroPace Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 5 months ago

NeuroPace Reports First Quarter 2025 Financial Results


NeuroPace Provides Update on Tariff Status

Apr 14, 2025, 4:05 PM EDT - 6 months ago

NeuroPace Provides Update on Tariff Status


NeuroPace Announces Refocusing of Product Portfolio

Apr 2, 2025, 4:05 PM EDT - 6 months ago

NeuroPace Announces Refocusing of Product Portfolio


NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:45 PM EST - 7 months ago

NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript


highnihilism
highnihilism Oct. 1 at 7:30 AM
$NPCE Neuropace Trade Count: 3 | Total $: 7.3 K | 1.43 × 90-Day Avg $: 5.1 K | Call $: 7.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $TUR iShares MSCI Turkey ETF Trade Count: 42 | Total $: 9.7 K | 0.32 × 90-Day Avg $: 30.1 K | Call $: 7.3 K | Put $: 2.4 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CNO Cno Finl Group Trade Count: 1 | Total $: 7.3 K | 2.79 × 90-Day Avg $: 2.6 K | Call $: 7.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $OCFT Oneconnect Financial Technology Trade Count: 5 | Total $: 7.3 K | 0.61 × 90-Day Avg $: 11.9 K | Call $: 7.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
Jonjon1234
Jonjon1234 Sep. 17 at 8:10 PM
$NPCE Drug resistant Epilepsy check! Focal and generalized Epilepsy in the not so distant future. Be patient with $NPCE as it’s the early innings.
1 · Reply
highnihilism
highnihilism Sep. 17 at 11:32 AM
IWM: Russell 2000 → $CBNK Capital Bancorp $NPCE Neuropace $HBT HBT Financial $DSGR Distribution Solutions $QCRH QCR
0 · Reply
HodlCommander
HodlCommander Sep. 12 at 5:46 PM
AlphaBriefing’s deep dive into quantum sensors in living cells and BCIs also features $NPCE (Neuropace). An interesting angle for neurotech investors. Read the article: https://www.alphabriefing.com/quantum-sensors-inside-living-cells-the-next-frontier-for-brain-computer-interfaces/
0 · Reply
johnemac
johnemac Aug. 25 at 3:54 PM
$NPCE Purely antidote but my son has not had a seizure since his Feb surgery with RNS and his wife comments on his improved memory, both goals for the surgery. Given good earnings, margins, forecasts and upcoming study results this should be higher but multiple factors.
0 · Reply
jacksonjohn750
jacksonjohn750 Aug. 19 at 1:26 PM
$NPCE will FDA knock them?
1 · Reply
CH_Expat
CH_Expat Aug. 15 at 4:58 PM
$NPCE @RocketThief You already pulled the trigger?
1 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:00 PM
Wells Fargo has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Overweight with a target price of 17 → 15.
0 · Reply
DonCorleone77
DonCorleone77 Aug. 12 at 8:28 PM
$NPCE NeuroPace reports Q2 EPS (26c), consensus (22c) -- Q2 revenue $23.52M, consensus $23.08M. -- Raises FY25 revenue view to $94M-$98M from $93M-$97M, consensus $94.78M. -- On track to submit Nautilus data to FDA in 2H
0 · Reply
ChessGM
ChessGM Aug. 6 at 4:46 PM
"Heads up alert! Upcoming earnings on Tuesday, 8/12/2025 for $NPCE Bullish (7.8) ### Financial Analysis NeuroPace, Inc. (NASDAQ: NPCE) is demonstrating considerable momentum in the medical technology sector, particularly in the niche of epilepsy management with its neurostimulator devices. The company's strategic response to the Centers for Medicare & Medicaid Services (CMS) decision to maintain the current reimbursement structure is crucial, as it ensures consistent revenue streams from its primary product offerings. As NeuroPace approaches its financial results announcement for the second quarter of 2025, expectations are centered around continued revenue growth and operational efficiency improvements under the new CFO, Patrick F. Williams. The company's P/E ratio, while not directly stated, is expected to reflect its rapid growth phase, potentially higher than industry averages due to the strategic market position and innovation-driven portfolio. NeuroPace's EPS growth is anticipated to be robust, aligning with the broader trend of increasing adoption of neurostimulator technology. Revenue forecasts are optimistic, bolstered by the maintained CMS reimbursement strategy, which is expected to drive both top-line growth and market confidence. Compared to industry peers such as AngioDynamics (ANGO), NeuroPace's focus on niche markets and specialized technology provides a competitive edge, although it also subjects the company to specific regulatory and market risks. ### Upcoming Earnings Report NeuroPace is scheduled to release its second-quarter 2025 financial results on August 12. Historically, the company has shown a pattern of steady financial improvement, and analyst consensus estimates suggest a continuation of this trend. The upcoming report is expected to highlight revenue growth and potential EPS improvements, driven by strategic decisions and operational refinements. Analyst consensus is cautiously optimistic, predicting that the company's recent management changes and strategic focus will positively impact the stock. The potential impact on the stock will largely depend on whether the company meets or exceeds these expectations, with a significant beat likely to further enhance investor sentiment. ### Sector Performance NeuroPace operates within the broader medical technology sector, which has been experiencing robust growth driven by innovation and increased healthcare spending. The sector's performance is marked by a strong demand for cutting-edge medical devices and technologies, particularly those addressing chronic conditions like epilepsy. Companies within this sector are benefiting from favorable regulatory environments and advancements in healthcare technology. NeuroPace, with its specialized focus, is well-positioned to capitalize on these trends, though it remains crucial for the company to navigate the regulatory landscape effectively to maintain its growth trajectory. - Funds were net buyers of $NPCE during the previous reporting quarter. - Funds with large holdings in $NPCE include: - OrbiMed Advisors LLC, MV: $42MM. Fund Rank: 55% www.orbimed.com - Soleus Capital , MV: $32MM. Fund Rank: 54% - First Light Asset Management LLC, MV: $19MM. New position. Fund Rank: 55% www.firstlightam.com - Armistice Capital LLC, MV: $14MM. Fund Rank: 72% www.armisticecapital.com - Deerfield Management Co, MV: $6MM. New position. Fund Rank: 90% www.deerfield.com - Last 10 days performance: -3% - Last 30 days performance: -16% - Last 90 days performance: -28% Some of the latest news articles: - Title: Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates Publication Date: 8/5/2025 12:25:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/orthofix-ofix-q2-earnings-revenues-122503319.html?.tsrc=rss - Title: NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases Publication Date: 8/1/2025 11:30:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/neuropace-commends-cms-maintaining-fy25-113000625.html?.tsrc=rss - Title: NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 Publication Date: 7/29/2025 8:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/neuropace-report-second-quarter-2025-200500610.html?.tsrc=rss - Title: AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates Publication Date: 7/15/2025 11:40:02 AM, Source: yahoo URL: https://finance.yahoo.com/news/angiodynamics-ango-reports-q4-loss-114002208.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."
0 · Reply
HypnoTrader
HypnoTrader Aug. 1 at 1:24 AM
$DCTH $NPCE $CLPT $MYO IHI broke to the downside today by almost 3%. extremely unusual. Market is going nuts....
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 9:17 PM
$NPCE Brilliant piece that captures NPCE's situation perfectly. So if you want to update your understanding of NPCE or get to know NPCE better, this is essential reading. https://beyondspx.com/article/neuropace-unlocking-epilepsy-s-code-with-brain-responsive-tech-nasdaq-npce
2 · Reply
Arcides
Arcides Jul. 25 at 9:32 PM
$NPCE pure downtrend
0 · Reply
RocketThief
RocketThief Jul. 11 at 3:09 PM
$NPCE waiting for a bit lower…
1 · Reply
jacksonjohn750
jacksonjohn750 Jul. 7 at 12:47 PM
$NPCE Trump will save us, but Obama and biden and Clinton.. if it goes down
0 · Reply
jacksonjohn750
jacksonjohn750 Jun. 18 at 6:44 PM
$NPCE @Scoops1212 we need another endorsement from you and Trump
1 · Reply
zoey1970
zoey1970 Jun. 13 at 3:21 PM
$MDT How Next-Gen Implants Are Making Seizure Prevention Smarter and Safer Than Ever An implantable chip could soon spot early epilepsy signals and intervene, significantly enhancing patients’ quality of life. At the heart of this innovation are Spiking Neural Networks (SNNs), a form of artificial intelligence that mimics the brain’s efficiency. These neuromorphic implantables, built on SNNs, mark notable progress toward energy-efficient AI, contrasting with traditional Artificial Neural Networks (ANNs) that operate nonstop like constant light sources. SNNs, in contrast, utilize event-triggered “spikes” (brief electrical pulses), activating only as needed and thereby slashing energy use—a vital advantage for medical tools. Read more here if interested...https://neuromorphiccore.ai/how-next-gen-implants-are-making-seizure-prevention-smarter-and-safer-than-ever/ $BSX $ABT $NPCE $LIVN
0 · Reply
jacksonjohn750
jacksonjohn750 Jun. 11 at 11:42 PM
$NPCE @Scoops1212 Will Trump and RFK save us?
1 · Reply
QuiverQuant
QuiverQuant Jun. 4 at 9:26 PM
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives Read more on $NPCE: https://www.quiverquant.com/news/NeuroPace%2C+Inc.+Secures+%2475+Million+Credit+Facility+from+MidCap+Financial+to+Support+Growth+Initiatives
0 · Reply
jacksonjohn750
jacksonjohn750 May. 30 at 5:13 PM
$NPCE Taco time? @Scoops1212
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 4:49 PM
$NPCE just unveiled promising one-year results from its NAUTILUS trial, but the stock tumbled 28.4%! 🤔 The RNS System shows promising potential for idiopathic generalized epilepsy, potentially expanding its market reach and driving revenue growth. Yet, the market reacted sharply — a mismatch? Discover why this could be a strategic opportunity or a cautionary tale 👉 https://www.zacks.com/commentary/2478445/npce-stock-tumbles-despite-positive-one-year-data-from-nautilus-trial?cid=sm-stocktwits-2-2478445-body&ADID=SYND_STOCKTWITS_TWEET_2_2478445_BODY
0 · Reply
jacksonjohn750
jacksonjohn750 May. 28 at 3:54 PM
$NPCE bought a few shares to support my MAGA friend
0 · Reply